Calvin Snipes, MD
Internal Medicine · Easley, SCNPI 1225023484
Payments from drug & device makers
Across 289 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$796
- Johnson & Johnson$475
- Lilly USA, LLC$394
- Amgen$387
- Novartis$352
- AbbVie$286
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,463100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $796 |
| Johnson & Johnson | 27 | $475 |
| Lilly USA, LLC | 26 | $394 |
| Amgen | 27 | $387 |
| Novartis | 18 | $352 |
| AbbVie(2 entities) | 18 | $286 |
| GSK | 18 | $240 |
| Pfizer | 13 | $188 |
| AstraZeneca | 12 | $165 |
| Dexcom, Inc. | 7 | $123 |
| Bayer | 8 | $122 |
| Abbott | 6 | $114 |
| Boehringer Ingelheim | 6 | $104 |
| Sanofi-aventis U.S. LLC | 5 | $80 |
| Merck | 5 | $79 |
| Amarin Pharma, Inc. | 3 | $59 |
| Antares Pharma, Inc. | 3 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Eisai Inc. | 3 | $38 |
| Sunovion Pharmaceuticals Inc. | 4 | $36 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Intuity Medical Inc | 1 | $27 |
| Clarus Therapeutics Inc. | 2 | $26 |
| Inari Medical, Inc. | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Gilead | 1 | $22 |
| Lundbeck LLC | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Exact Sciences | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,463 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 121 | $163,399 |
| EliquisApixaban | 132 | $105,840 |
| OzempicSemaglutide | 93 | $90,315 |
| JardianceEmpagliflozin | 71 | $75,685 |
| Repatha SureclickEvolocumab | 68 | $60,663 |
| ProliaDenosumab | 32 | $55,905 |
| JanuviaSitagliptin Phosphate | 60 | $53,816 |
| XareltoRivaroxaban | 65 | $48,753 |
| Tresiba Flextouch U-100Insulin Degludec | 76 | $43,566 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $42,363 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $27,334 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $22,103 |
| MyrbetriqMirabegron | 34 | $19,638 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $19,157 |
| FarxigaDapagliflozin Propanediol | 23 | $19,138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $394 | $163,399121 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Synjardy | $104 | $111,710124 claims |
| Novo NordiskOzempic, Rybelsus | $796 | $109,275104 claims |
| PfizerEliquis | $188 | $105,840132 claims |
| AmgenProlia | $387 | $55,90532 claims |
| MerckJanuvia | $79 | $53,81660 claims |
| Johnson & JohnsonXarelto | $475 | $48,75365 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $240 | $27,24341 claims |
| AbbVieLinzess, Creon | $286 | $22,28134 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $19,63834 claims |
| AstraZenecaFarxiga | $165 | $19,13823 claims |
| BayerKerendia | $122 | $7,78012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Easley
- David ChangEasley$13K
- Roger BoatwrightEasley$13K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.